Madhya Pradesh Online Journal

Metastatic Colorectal Cancer Pipeline Insight, Clinical Trial Analysis, NDA Approvals | 140+ Companies and 140+ Drugs

 Breaking News
  • No posts were found

Metastatic Colorectal Cancer Pipeline Insight, Clinical Trial Analysis, NDA Approvals | 140+ Companies and 140+ Drugs

January 17
16:34 2023
Metastatic Colorectal Cancer Pipeline Insight, Clinical Trial Analysis, NDA Approvals | 140+ Companies and 140+ Drugs

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight 2023,” report provides comprehensive insights about 140+ companies and 140+ pipeline drugs in Metastatic Colorectal Cancer pipeline landscape. It covers the Metastatic Colorectal Cancer pipeline drug profiles, including Metastatic Colorectal Cancer clinical trial and nonclinical stage products. It also covers the Metastatic Colorectal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Metastatic Colorectal Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Metastatic Colorectal Cancer clinical trial studies, Metastatic Colorectal Cancer NDA approvals (if any), and product development activities comprising the technology, Metastatic Colorectal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Metastatic Colorectal Cancer Pipeline Report

  • Over 140+ Metastatic Colorectal Cancer companies are evaluating 140+ Gastric Cancer pipeline therapies in various stages of development, and their anticipated acceptance in the Metastatic Colorectal Cancer market would significantly increase market revenue.
  • The leading Metastatic Colorectal Cancer Companies are working to develop drug candidate to improve Metastatic Colorectal Cancer treatment scenario include G1 Therapeutics, Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Celyad Oncology SA, Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences Inc., Merck, Array BioPharma, Sumitomo Dainippon Pharma Co., Ltd, Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, Genentech, Qilu Pharmaceutical Co., Ltd., Suzhou Zelgen Biopharmaceuticals Co., Ltd, Henlix Biotech, Scandion Oncology A/S, AB Science, Aadi, LLC, Novartis, Roche, Celyad Oncology SA, Boehringer Ingelheim, Amgen, Isofol Medical, Treos Bio Zrt, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, and others.
  • Promising Metastatic Colorectal Cancer Pipeline Therapies include CMAB009 plus Irinotecan, Irinotecan-only and sequential-CMAB009, Trifluridin/Tipiracil, etrumadenant, zimberelimab, mFOLFOX-6 regimen, Pembrolizumab, Binimetinib, Oxaliplatin, FOLFIRI, FOLFOX, Bevacizumab, Oxaliplatin, Leucovorin, and others.
  • The Metastatic Colorectal Cancer Companies and academics are working to assess challenges and seek opportunities that could influence Metastatic Colorectal cancer R&D. The Metastatic Colorectal Cancer pipeline therapies under development are focused on novel approaches to treat/improve Metastatic Colorectal cancer.
  • Metastatic Colorectal cancer pipeline report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.

 

To explore more information on the latest breakthroughs in the Metastatic Colorectal Cancer treatment landscape of the report, click here @ Metastatic Colorectal Cancer Pipeline Outlook

 

Recent Developmental Activities in the Metastatic Colorectal Cancer Treatment Landscape

  • On November 18, 2021 Gilead Sciences announced that it had exercised its options to three of Arcus Biosciences’ programs. Two are anti-TIGIT molecules, domvanalimab and AB308, and the other is etrumadenant and quemliclustat. The two companies have also added a research collaboration deal. Arcus shares popped 15% at the news.
  • In September 2021, Erasca, announced a clinical trial collaboration and supply agreement with Pfizer Inc. for the BRAF inhibitor encorafenib (BRAFTOVI®). This agreement will support a clinical proof-of-concept study evaluating ERAS-007, an oral ERK1/2 inhibitor, in combination with encorafenib and the EGFR inhibitor cetuximab for the treatment of patients with BRAF V600E-mutant mCRC.
  • In December 2021, Rottapharm Biotech announced a clinical collaboration with Agenus’ balstilimab (anti-PD-1) in collaboration with its lead candidate CR6086 in advanced colorectal cancer at the National Cancer Institute. Rottapharm Biotech’s clinical collaboration with Agenus offers a promising new combination therapy for patients with advanced pMMR/MSS mCRC where there is a high unmet need, and for a further range of potential applications in other immunotherapy-resistant tumors.
  • On 11 May 2021, Shanghai Henlius Biotech and NeuPharma entered into a drug technology license agreement. NeuPharma will grant the Company a sublicensable exclusive license for related licensed patents and licensed know-how necessary or reasonably useful for the Company to research, develop, produce and commercialize the Licensed Product within the Licensed Territory (China).
  • In November 2021, The US FDA granted a fast track designation to arfolitixorin as a potential therapeutic option for patients with metastatic colorectal cancer (mCRC). This serves as a strong external validation of arfolitixorin’s potential to benefit patients with this devastating disease.
  • In January 2022, Gritstone bio, Inc. announced that the first patient was enrolled for inclusion in the Phase 2/3 GRANITE-CRC-1L trial. The trial evaluates the individualized neoantigen vaccine GRANITE in combination with immune checkpoint blockade for the first line (1L) maintenance treatment of newly diagnosed patients with metastatic, microsatellite-stable colorectal cancer (MSS-CRC). This trial has registrational intent and has been discussed previously with the FDA.

 

Metastatic Colorectal Cancer Overview

Colorectal cancer (CRC) is the third most common, with metastasis being the major cause of death in the majority of patients. Common sites of distant metastasis are the liver and the peritoneum. CRC starts in the colon or the rectum. These cancers can also be called colon cancer or rectal cancer, depending on where they start. Colon cancer and rectal cancer are often grouped because they have many features in common. CRC may develop when polyps, mushroom-like growths inside the colon, grow and become cancerous or cells along the lining of the colon or rectum mutate and grow out of control, forming a tumor. CRC that spreads, or metastasizes, to the lungs, liver or any other organ is called metastatic colorectal cancer (mCRC).

 

Request a sample and discover the recent advances in Metastatic Colorectal Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Metastatic Colorectal Cancer Treatment Landscape

 

Metastatic Colorectal Cancer Emerging Drugs Profile

 

Trilaciclib: G1 Therapeutics

Corsela (Trilaciclib) is a small-molecule, short-acting, inhibitor of cyclin-dependent kinases (CDK) 4 and 6 developed by G1 Therapeutics for its myeloprotection and potential antitumor efficacy and safety benefits in combination with cancer chemotherapy. CDKs govern cell cycle progression, and trilaciclib induces a transient, reversible G1 cell cycle arrest of proliferating hematopoietic stem and progenitor cells in bone marrow, thus protecting them from damage during chemotherapy.  It is a novel therapeutic approach, which is given before chemotherapy that temporarily blocks progression through the cell cycle. This provides two benefits. First, it proactively helps protect HSPCs in bone marrow leading to preservation of neutrophils, erythrocytes, and platelets (called myeloprotection) which reduces the occurrences and severity of neutropenia and other myelosuppressive consequences of chemotherapy.

 

Famitinib: Jiangsu Hengrui Medicine

Famitinib is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Famitinib binds to and inhibits several RTKs, dysregulated in a variety of tumors, including stem cell factor receptor (c-Kit; SCFR), vascular endothelial growth factor receptor (VEGFR) 2 and 3, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinases Flt1 and Flt3. Inhibition of these RTKs may result in an inhibition of tumor growth and angiogenesis, and eventually tumor regression in tumor cells overexpressing these RTKs. Famitinib is being evaluated in Phase III clinical trial to treat metastatic colorectal cancer.

 

CMAB009: Mabpharm Limitied

CMAB009 is a recombinant, human/mouse chimeric monoclonal antibody (mAb) that binds specifically to the extracellular domain of EGFR. It is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and k light chain constant regions and it is expressed by Chinese hamster ovary cells. It has the same amino acid sequence as cetuximab (C225, Erbitux®) , but it has slightly different abilities for glycosylation and other post-translational modifications, and it is developed by Shanghai Zhangjiang Biotechnology Limited Company and produced by Biomabs. Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). CMAB009, a recombinant anti-EGFR monoclonal antibody with the same amino acid sequence as cetuximab is being evaluated in a Phase III study to treat metastatic colorectal cancer.

 

Trastuzumab Deruxtecan: Daiichi Sankyo

Trastuzumab deruxtecan is a HER2 directed antibody drug conjugate (ADC). Designed using Daiichi Sankyo’s proprietary DXd ADC technology, trastuzumab deruxtecan is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced program in AstraZeneca’s ADC scientific platform.  ADCs are targeted cancer medicines that deliver cytotoxic chemotherapy (“payload”) to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells. Trastuzumab deruxtecan is comprised of a HER2 monoclonal antibody attached to a novel topoisomerase I inhibitor payload by a tetrapeptide-based linker.

 

SCO-101: Scandion Oncology

Scandion Oncology’s leading product – SCO101 – is ingested as a capsule and has in preclinical studies shown to significantly improve the effect of standard cancer treatment when given in combination with the cancer drug. Moreover, SCO-101 inhibits key resistance mechanisms that allow the standardized cancer treatment to be effective again in patients with drug resistant disease. Therefore, SCO-101 has the potential to make the chemotherapy much more effective without increasing side effects for patients. The target indications are metastatic colorectal cancer and inoperable or metastatic pancreatic cancer, with more indications likely to follow. Currently it is being evaluated in Phase II stage of development to treat patients with metastatic colorectal cancer.

 

BEY 1107: BeyondBio

Avotaciclib (formerly BEY 1107) is a CDK1 inhibitor being developed by BeyondBio for the treatment of pancreatic cancer and glioblastoma. The drug induces apoptosis through cell suicide mechanism by synchronizing the G2/M cell cycle phases of the glioblastoma and pancreatic cancer cells. Currently it is being evaluated in Phase I/II stage of development to treat metastatic colorectal cancer.

 

Etrumadenant: Arcus Biosciences

Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist in the clinic, is designed to maximally inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes (mainly CD8+ T cells and NK cells) and myeloid cells (dendritic cells, macrophages), mediated by A2aR and A2bR, respectively. A2bR is also upregulated by certain cancer cells, such as in prostate cancer and KRAS- mutated cancers. As a result, Etrumadenant may uniquely block adenosine’s immunosuppressive and cancer cell-intrinsic effects. Developed specifically for the oncology setting, Etrumadenant achieves high penetration of tumor tissue, robust potency in the presence of high adenosine concentrations, and minimal shift in potency from non-specific protein binding. Etrumadenant has demonstrated a favorable safety profile with a variety of combination regimens and exhibits pharmacokinetics / pharmacodynamics consistent with once-daily dosing. AB928 is currently being evaluated in several Phase I/II studies across multiple indications including metastatic colorectal cancer.

 

Metastatic Colorectal Cancer Pipeline Therapeutics Assessment

There are approx. 140+ key companies which are developing the Metastatic Colorectal cancer pipeline therapies. The Metastatic Colorectal cancer Companies which have their Metastatic Colorectal cancer drug candidates in the most advanced stage, i.e. phase III include, G1 Therapeutics.

 

For further information, refer to the detailed Metastatic Colorectal Cancer Unmet Needs, Metastatic Colorectal Cancer Market Drivers, and Metastatic Colorectal Cancer Market Barriers, click here @ Metastatic Colorectal Cancer Ongoing Clinical Trial Analysis

 

Scope of the Metastatic Colorectal Cancer Pipeline Report

  • Coverage- Global
  • Metastatic Colorectal cancer Companies- G1 Therapeutics, Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Celyad Oncology SA, Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences Inc., Merck, Array BioPharma, Sumitomo Dainippon Pharma Co., Ltd, Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, Genentech, Qilu Pharmaceutical Co., Ltd., Suzhou Zelgen Biopharmaceuticals Co., Ltd, Henlix Biotech, Scandion Oncology A/S, AB Science, Aadi, LLC, Novartis, Roche, Celyad Oncology SA, Boehringer Ingelheim, Amgen, Isofol Medical, Treos Bio Zrt, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, and others.
  • Metastatic Colorectal cancer Pipeline Therapies- CMAB009 plus Irinotecan, Irinotecan-only and sequential-CMAB009, Trifluridin/Tipiracil, etrumadenant, zimberelimab, mFOLFOX-6 regimen, Pembrolizumab, Binimetinib, Oxaliplatin, FOLFIRI, FOLFOX, Bevacizumab, Oxaliplatin, Leucovorin, and others.
  • Metastatic Colorectal Cancer Pipeline Segmentation: Phases, Product Type, Mechanism of Action, Route of Administration, Molecule Type

 

Table of Content

  1. Introduction
  2. Metastatic Colorectal cancer Executive Summary
  3. Metastatic Colorectal cancer: Overview
  4. Metastatic Colorectal cancer Pipeline Therapeutics
  5. Metastatic Colorectal cancer Therapeutic Assessment
  6. Metastatic Colorectal cancer – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Trilaciclib: G1 Therapeutics
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II/III)
  11. SHR 1701: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
  12. Drug profiles in the detailed report…..
  13. Mid Stage Products (Phase II)
  14. Trastuzumab Deruxtecan: Daiichi Sankyo
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I/II)
  17. NKTR-255: Nektar Therapeutics
  18. Drug profiles in the detailed report…..
  19. Early Stage Products (Phase I)
  20. Talimogene Laherparepvec: Amgen
  21. Drug profiles in the detailed report…..
  22. Preclinical and Discovery Stage Products
  23. PCS11T: Processa Pharmaceuticals
  24. Drug profiles in the detailed report…..
  25. Inactive Products
  26. Metastatic Colorectal cancer Key Companies
  27. Metastatic Colorectal cancer Key Products
  28. Metastatic Colorectal cancer- Unmet Needs
  29. Metastatic Colorectal cancer- Market Drivers and Barriers
  30. Metastatic Colorectal cancer- Future Perspectives and Conclusion
  31. Metastatic Colorectal cancer Analyst Views
  32. Metastatic Colorectal cancer Key Companies
  33. Appendix

 

Dive deep into rich insights for drugs for Metastatic Colorectal cancer Market Drivers and Metastatic Colorectal cancer Market Barriers, click here @ Metastatic Colorectal cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/